Novel Oral Anticoagulants at 10: An Assessment of their Safety and Contemporary Use in Atrial Fibrillation

Published: 04 March 2021

  • Views:

    Views Icon 394
  • Likes:

    Heart Icon 0

Overview

Full programme

  • Views:

    Views Icon 394
  • Likes:

    Heart Icon 0

Overview

This roundtable will discuss real world data and meta-analysis for patients undergoing intervention/ablation and will assist physicians to identify and select appropriate treatment strategies with NOACs in AF patients in need of further ablation or intervention as well as to identify which individuals with AF should be initiated on NOAC therapy without delay.

This activity has been supported via an educational grant from Boehringer Ingelheim

Learning Objectives

  • Identify which individuals with atrial fibrillation should be initiated on NOAC therapy without delay
  • Interpret safety and cardiovascular data from RCTs in the context of real-world experience
  • Select appropriate treatment strategies with NOACs in atrial fibrillation patients in need of further ablation or intervention
  • Review the reversal options open to individuals experiencing a bleeding event whilst on treatment with a NOAC

Target Audience

  • Cardiologists
  • Interventional Cardiologists

Series overview

Part 1

When to Initiate a NOAC and Patient Suitability (data presentation)

An overview of current guidelines

1 session

Part 2

Overview of Safety and Cardiovascular Data

a. Safety and cardiovascular data from RCTs b. Real-world and meta-analyses

1 session

Part 3

Dealing with Complications:

Major bleeding events and reversal

1 session

Part 4

Discussion on Safety Rates and Patient Suitability (Panel Discussion Session)

Panel recommendations of NOAC choice according to different patient populations

1 session

  • Panel discussion moderated by John Eikelboom

    Watch now

Part 5

NOAC Use with Ablation and Intervention

a. Guideline recommendations and current trends b. Use of NOACs with ablation in Japan: clinical data

1 session

Part 6

Discussion on the Current Use of NOACs in Japan

a. Use in elderly/very old pts b. Under-dosing of NOACs c. Current unmet needs

1 session

  • Panel Discussion Moderated by John Eikelboom

    Watch now

Faculty biographies